Pre-formulation

О курсе

In this course we will focus on how active compounds are developed into a formulation suitable for dosing in animal studies and early human clinical trials.  Factors such as the route of administration, enhancing the solubility of the drug substance, the crystalline form of the drug substance, drug substance vs. drug product, storage requirements, and how special requirements of the patient population play a role in the design of an ideal formulation will be covered.  Finally, some of the differences encountered when formulating a biologic vs. a small molecule will be discussed. Target audience: This course is suitable for life scientists, clinicians, and individuals from fields that support drug discovery (e.g., patents, finance, licensing, etc.) interested in learning more about the pharmaceutical/biotechnology sector. Advanced undergraduate coursework or practical familiarity/working knowledge in biological sciences and organic chemistry is recommended.

Навыки, которые вы освоите

Учитесь у экспертов

Erland Stevens, PhD

James G. Martin Professor of Chemistry, Davidson College

W. Ross Tracey, PhD

Associate Director, Biomedical Research Learning, Novartis

Douglas S. Auld, PhD

Associate Director, Discovery Sciences, Biomedical Research, Novartis

Alan P. Brown, PhD, DABT

Director, Preclinical Safety, Biomedical Research, Novartis

Sujal Deshmukh, PhD

Director, Pharmacokinetic Sciences, Biomedical Research, Novartis

Stephanie Dodd, MSc.

Associate Director, Chemical & Pharmaceutical Profiling, Development, Novartis

Sabine Guth, PhD

Director, Diseases Of Aging and Regenerative Medicine, Biomedical Research, Novartis

Thomas M. Smith, PhD

Associate Director, Early Strategic Partnerships Biomedical Research, Novartis